Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro

AAPS Journal

Volumn 16, Issue 2, 2014, Pages 181-193

  Agrahari, Vivek ^a   Zhang, Chi ^a   Zhang, Tao ^a   Li, Wenjing ^a   Gounev, Todor K ^a   Oyler, Nathan A ^a   Youan, Bi Botti C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

experimental design; hyaluronic acid; hyaluronidase; microbicide; nanoparticles

Indexed keywords

1 ETHYL 3 [3 DIMETHYLAMINOPROPYL]CARBODIIMIDE; ACETONE; ADIPIC ACID; CYANAMIDE; HYALURONIC ACID; HYALURONIDASE; NANOPARTICLE; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DEGRADATION KINETICS; DRUG FORMULATION; DRUG RELEASE; ENZYME DEGRADATION; EXPERIMENTAL DESIGN; FEMALE; GEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFRARED SPECTROSCOPY; LACTOBACILLUS CRISPATUS; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; POLYDISPERSITY INDEX; REACTION TIME; ZETA POTENTIAL;

ANTI-HIV AGENTS; CELL LINE; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; VAGINA;

EID: 84895877111     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9546-7     Document Type: Article

References (66)

1. Omar RF, Bergeron MG. The future of microbicides. Int J Infect Dis. 2011;15(10):e656-60.
2. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10(3):315-36. (Pubitemid 38072766)
3. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009;11(1):78-87.
4. Grammen C, Augustijns P, Brouwers J. In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients.Antivir Res. 2012;96(2):226-33.
5. Gupta KM, Barnes SR, Tangaro RA, Roberts MC, Owen DH, Katz DF, et al. Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci. 2007;96(3):670-81. (Pubitemid 46466087)
6. Ma X, Wang D, Wu Y, Ho RJ, Jia L, Guo P, et al. AIDS treatment with novel anti-HIV compounds improved by nano-technology. AAPS J. 2010;12(3):272-8.
7. Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol. 2009;83(21):11196-200.
8. Tevi-Benissan C, Belec L, Levy M, Schneider-Fauveau V, Si Mohamed A, Hallouin MC, et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol. 1997;4(3):367-74. (Pubitemid 27239700)
9. Wagner G, Ottesen B. Vaginal physiology during menstruation. Ann Intern Med. 1982;96(6 Pt 2):921-3. (Pubitemid 12088899)
10. Fox CA, Meldrum SJ, Watson BW. Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil. 1973;33(1):69-75.
11. Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release. 2010;141(1):2-12.
12. Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release. 2011;156(2):231-8.
13. Prestwich GD. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release. 2011;155(2):193-9.
14. Schanté CE, Zubera G, Herlin C, Vandamme TF. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr Polym. 2011;85:469-89.
15. Swyer GI. The hyaluronidase content of semen. Biochem J. 1947;41(3):409-13.
16. Stern R, Kogan G, Jedrzejas MJ, Soltes L. The many ways to cleave hyaluronan. Biotechnol Adv. 2007;25(6):537-57. (Pubitemid 47464847)
17. Bajaj G, Kim MR, Mohammed SI, Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release. 2012;158(3):386-92.
18. Zidan AS, Spinks C, Fortunak J, Habib M, Khan MA. Near-infrared investigations of novel anti-HIV tenofovir liposomes. AAPS J. 2010;12(2):202-14.
19. Choi SU, Bui T, Ho RJ. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci. 2008;97(2):931-43. (Pubitemid 351293892)
20. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
21. Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, et al. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. Antivir Res. 2012;96(2):221-5.
22. Saxena BB, Han YA, Fu D, Rathnam P, Singh M, Laurence J, et al. Sustained release of microbicides by newly engineered vaginal rings. AIDS. 2009;23(8):917-22.
23. Alukda D, Sturgis T, Youan BB. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci. 2011;100(8):3345-56.
24. Meng J, Sturgis TF, Youan BB. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci. 2011;44(1-2):57-67.
25. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm. 2011;79(3):526-36.
26. Zhang T, Zhang C, Agrahari V, Murowchick JB, Oyler NA, Youan BB. Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention. Antivir Res. 2013;97(3):334-46.
27. Hu Z, Xia X, Tang L (inventors). Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles. United States patent 7,601,704 B2. 2009 October 13.
28. Montgomery DC. Design and analysis of experiments. 6th ed. New York: Wiley; 2005.
29. Pitarresi G, Craparo EF, Palumbo FS, Carlisi B, Giammona G. Composite nanoparticles based on hyaluronic acid chemically cross-linked with alpha, beta-polyaspartylhydrazide. Biomacromolecules. 2007;8(6):1890-8. (Pubitemid 47009968)
30. Zhang Y, Jiang T, Zhang Q, Wang S. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property. Eur J Pharm Biopharm. 2010;76(1):17-23.
31. Agrahari V, Youan BB. Sensitive and rapid HPLC quantification of tenofovir from hyaluronic acid-based nanomedicine. AAPS PharmSciTech. 2012;13(1):202-10.
32. De Iaco PA, Muzzupapa G, Bigon E, Pressato D, Dona M, Pavesio A, et al. Efficacy of a hyaluronan derivative gel in postsurgical adhesion prevention in the presence of inadequate hemostasis. Surgery. 2001;130(1):60- 4.
33. Koppel DE. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: the method of cumulants. J Chem Phys. 1972;57:4814-22.
34. Katzel U, Vorbau M, Stintz M, Gottschalk-Gaudig T, Barthel H. Dynamic light scattering for the characterization of polydisperse fractal systems: II. Relation between structure and DLS results. Part Part Syst Charact. 2008;25:19-30. (Pubitemid 351613113)
35. Hackley V, Ferraris C. The use of nomenclature in dispersion science and technology, NIST Recommended Practice Guide: SP; 2001
36. Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem. 1962;4:330-4.
37. De Salegui M, Plonska H, Pigman W. A comparison of serum and testicular hyaluronidase. Arch Biochem Biophys. 1967;121(3):548-54.
38. Highsmith S, Garvin Jr JH, Chipman DM. Mechanism of action of bovine testicular hyaluronidase. Mapping of the active site. J Biol Chem. 1975;250(18):7473-80.
39. Honda T, Kaneiwa T, Mizumoto S, Sugahara K, Yamada S. Hyaluronidases have strong hydrolytic activity toward chondroitin 4-sulfate comparable to that for hyaluronan. Biomolecules. 2012;2(4):549-63.
40. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001;20(8):499-508. (Pubitemid 33109098)
41. Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl. 2005;26(4):459-69. (Pubitemid 40847857)
42. Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999;59(2):91-5. (Pubitemid 29244754)
43. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010;5(2):e9310.
44. Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, Lewis G, et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother. 2008;52(5):1768-81. (Pubitemid 351614671)
45. Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med. 1991;174(1):289-92.
46. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33. (Pubitemid 32288781)
47. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nano-precipitation methods. Pharm Res. 2004;21(8):1428-39. (Pubitemid 39149658)
48. Scott JE, Heatley F. Hyaluronan forms specific stable tertiary structures in aqueous solution: a 13C NMR study. Proc Natl Acad Sci U S A. 1999;96(9):4850-5. (Pubitemid 29214500)
49. Zhang G, Niu A, Peng S, Jiang M, Tu Y, Li M, et al. Formation of novel polymeric nanoparticles. Acc Chem Res. 2001;34(3):249-56. (Pubitemid 32816386)
50. Zhang T, Murowchick J, Youan BB. Optimization of formulation variables affecting spray-dried oily core nanocapsules by response surface methodology. J Pharm Sci. 2011;100(3):1031-44.
51. Zhong SP, Campoccia D, Doherty PJ, Williams RL, Benedetti L, Williams DF. Biodegradation of hyaluronic acid derivatives by hyaluronidase. Biomaterials. 1994;15(5):359-65. (Pubitemid 24127319)
52. Sugrue S. Predicting and controlling colloid suspension stability using electrophoretic mobility and particle size measurements. Am Lab. 1992;24:64-71.
53. Moebus K, Siepmann J, Bodmeier R. Alginate-poloxamer microparticles for controlled drug delivery to mucosal tissue. Eur J Pharm Biopharm. 2009;72(1):42-53.
54. Sriamornsak P, Kennedy RA. Effect of a small molecule on diffusion and swelling properties of selected polysaccharide gel beads. Carbohydr Polym. 2010;79(1):219-23.
55. Sriamornsak P, Nunthanid J, Cheewatanakornkool K, Manchun S. Effect of drug loading method on drug content and drug release from calcium pectinate gel beads. AAPS PharmSciTech. 2010;11(3):1315-9.
56. Lenormand H, Vincent JC. pH effects on the hyaluronan hydrolysis catalysed by hyaluronidase in the presence of proteins: Part II. The electrostatic hyaluronan - protein complexes. Carbohydr Polym. 2011;85:303-11.
57. Lowry KM, Beavers EM. Thermal stability of sodium hyaluronate in aqueous solution. J Biomed Mater Res. 1994;28(10):1239-44. (Pubitemid 24303149)
58. Vernasca C, Giori AM, Togni S (inventors). Hyaluronic acid compositions stabilised against the degrading effect of heat or enzymes. WO Patent 2,012,089,537. 2012 July 5.
59. Minaberry Y, Chiappetta DA, Sosnik A, Jobbagy M. Micro/nanostructured hyaluronic acid matrices with tuned swelling and drug release properties. Biomacromolecules. 2013;14(1):1-9.
60. Chouhan R, Bajpai A. Real time in vitro studies of doxorubicin release from PHEMA nanoparticles. J Nanobiotechnol. 2009;7(5):1- 12.
61. Ferir G, Vermeire K, Huskens D, Balzarini J, Van Damme EJ, Kehr JC, et al. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antivir Res. 2011;90(3):200-4.
62. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008;122(1):3-9.
63. Su WY, Chen YC, Lin FH. Injectable oxidized hyaluronic acid/adipic acid dihydrazide hydrogel for nucleus pulposus regeneration. Acta Biomater. 2010;6(8):3044-55.
64. Deng Y, Liu D, Du G, Li X, Chen J. Preparation and characterization of hyaluronan/chitosan scaffold crosslinked by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. Polym Int. 2007;56:738-45. (Pubitemid 46795740)
65. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World Health Organization reference values for human semen characteristics.Hum Reprod Updat. 2010;16(3):231-45.
66. Komei M, Isamu M, Tadao W, Takeko K. Activation of hyaluronidase by spermine and related diamines. 1959;7(1):123-6.